RedHill Biopharma

Edison Investment Research is terminating coverage on RedHill Biopharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Thematics

Latest

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

Audiovisual

Latest

Recce Pharmaceuticals – executive interview

VEON – executive interview with CFO Joop Brakenhoff

VEON – executive interview with CEO Kaan Terzioğlu

About Edison

About Edison

Careers

RedHill Biopharma (US: RDHL)

Latest Insights

Redhill Biopharma — Rapid COVID-19 Ph II/III programme progress

Redhill Biopharma — First quarter with significant sales; Cosmo deal

Redhill Biopharma — Rapid progress with COVID-19 programme

Redhill Biopharma — Movantik acquisition completed; sales booked

Sector

Financials

Research

Redhill Biopharma — TALICIA will dominate newsflow in H219

RedHill Biopharma — FDA accepts TALICIA’s NDA

RedHill Biopharma — Cosmo deal – new asset, stronger balance sheet

Redhill Biopharma — TALICIA launch for H. pylori in sight

Redhill Biopharma — TALICIA Ph III top-line data positive

Redhill Biopharma — Ph III with TALICIA data readout end-2018

RedHill BioPharma — RHB-104 data look good

RedHill BioPharma — Continued GI product growth, CD PhIII data in 3M

Redhill Biopharma — Commercial stage, GI-focused R&D pharma

Redhill Biopharma — Successful Phase II with BEKINDA for IBS-D

RedHill Biopharma — Positive Phase III with BEKINDA for gastroenteritis

RedHill BioPharma — Seeking recurring revenues; two readouts in 2017

RedHill Biopharma — Second GI product added to commercial portfolio

RedHill BioPharma — Transformation to commercial/R&D spec pharma

Redhill Biopharma — Update 12 January 2017

Redhill Biopharma — Update 24 November 2016

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time